-+ 0.00%
-+ 0.00%
-+ 0.00%

GE HEALTHCARE’S PHASE 2 RESULTS SUPPORT ADVANCEMENT OF INVESTIGATIONAL MANGANESE-BASED MRI CONTRAST AGENT MANGACICLANOL INTO PHASE 3 OF LUMINA CLINICAL TRIAL

Reuters·11/19/2026 13:00:03

Please log in to view news